tbuckley/cabot-search huggingface dataset:
Feasibility of risk stratified allocation to single versus tandem autologous SCT in multiple myeloma.
Authors: Matthew Risendal, Allison Hazlett, Roy T. Sabo, Priscilla Mpasi, Joan Bolling, William B. Clark, John McCarty, Harold M. Chung, Catherine H. Roberts, Amir A. Toor
Journal: Journal of Clinical Oncology (2012)

e18550 Background: Multiple myeloma (MM) is a plasma cell malignancy with variable prognosis depending on disease features such as β2m and cytogenetics. High dose therapy and stem cell transplantation (SCT) remains the current standard of care for MM, however the role of tandem SCT is controversial, particularly in the era of novel induction therapy. Methods: Our program has a practice of risk-stratified transplant allocation in MM patients referred for SCT, those with high-risk (HR) disease (β2m &gt;5.5, adverse cytogenetics, &gt;1st remission) are preferentially assigned tandem SCT, and those with standard risk (SR), a single SCT. Between 2008 and 2011, 129 MM patients underwent SCT, 43% SR patients received a single SCT (SRS), 22% HR received tandem SCT (HRT) &amp; 36% HR a single SCT (HRS). Median age at SCT was 57 years. Maintenance therapy was administered in 51% SRS, 57% HRT &amp; 67% HRS patients. Results: Complete response (CR) or very good partial response was achieved in 0.68, 0.72 and 0.80 for the HRT, HRS, and SRS groups. The HRT group (0.39) was more likely to achieve CR than HRS (0.20) (P=0.02). At a median follow up of 23.4 months, the overall survival for HRS was inferior to SRS (P=0.01) but there was no difference in the overall survival between HRT and SRS cohorts. Two-year survival rates were 0.81, 0.91 and 0.97 in the HRS, HRT and SRS cohorts (HRS vs. SRS P=0.02). This was attributable to a higher 1-year relapse rate in HRS (0.29) compared to HRT (0.07) and SRS (0.07) (P&lt;0.01). Conclusions: Using a risk-stratified allocation system, we report that HR MM patients undergoing tandem SCT have outcomes comparable to SR patients. However, HR MM patients receiving a single SCT have inferior outcomes compared to those with SR. Notably, higher rate of CR and a lower relapse rate were observed in the HRT cohort when compared to HRS. This suggests that greater depth of remission achieved in HR patients undergoing tandem SCT may result in longer time to relapse and survival advantage compared to HR patients receiving a single SCT. In contrast, a single SCT may suffice for SR MM patients. These results demonstrate that risk-stratification based on disease prognostic features is an important treatment consideration when planning high dose therapy in MM patients.
Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men
Authors: Jonathan P. Piccini, DaJuanicia N. Simon, Benjamin A. Steinberg, Laine Thomas, Larry A. Allen, Gregg C. Fonarow, Bernard Gersh, Elaine Hylek, Peter R. Kowey, James A. Reiffel, Gerald V. Naccarelli, Paul S. Chan, John A. Spertus, Eric D. Peterson
Journal: JAMA Cardiology (2016)

Despite the frequency of atrial fibrillation (AF) in clinical practice, relatively little is known about sex differences in symptoms and quality of life and how they may affect treatment and outcomes.To determine whether symptoms, quality of life, treatment, and outcomes differ between women and men with AF.This observational cohort study included 10 135 patients with AF. The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation is a prospective, nationwide, multicenter outpatient registry of patients with incident and prevalent AF enrolled at 176 sites between June 2010 and August 2011.Symptoms, quality of life as measured by Atrial Fibrillation Effects on Quality of Life scores, AF treatment, cardiovascular outcomes, stroke or non-central nervous system embolism, and all-cause mortality.Overall, 4293 of the cohort (42%) were female. Compared with men, women were older (77 years; interquartile range [IQR], 69-83, vs 73 years; IQR, 65-80; P < .001) and had higher median CHA2DS2-VASc scores (5; IQR, 4-6, vs 3; IQR, 2-5; P < .001), but less sleep apnea (578 [13.5%] vs 1264 [21.6%]; P < .001). Only 32.1% of women (n = 1378) were asymptomatic (European Heart Rhythm Association class I) compared with 42.5% of men (n = 2483) in unadjusted analyses (P < .001). Women had lower (more severe) unadjusted baseline overall Atrial Fibrillation Effects on Quality of Life scores (n = 2007; 80; IQR, 62-92 vs 83; IQR, 69-94; P < .001). Women had similar rates of anticoagulation and similar time in therapeutic range. In follow-up, women experienced lower risk-adjusted all-cause mortality (adjusted hazard ratio, 0.57; 95% CI, 0.49-0.67) and cardiovascular death (adjusted hazard ratio, 0.56; 95% CI, 0.44-0.72); however, they had a higher risk for stroke or non-central nervous system embolism (adjusted hazard ratio, 1.39; 95% CI, 1.05-1.84; P = .02) compared with men.Women with AF have more symptoms and worse quality of life. Despite higher risk, women have lower risk-adjusted all-cause and cardiovascular death compared with men, but higher stroke rates. Future studies should focus on how treatment and interventions specifically affect AF-related quality of life and cardiovascular outcomes in women.clinicaltrials.gov Identifier: NCT01165710.
Rotation anomaly in duplex kidney.
Authors: EMEL CEYLAN, PINAR OZGEN KIRATLI
Journal: Clinical Nuclear Medicine (2001)

From the Department of Nuclear Medicine, Hacettepe University Medical Centre, Ankara, Turkey Received for publication July 19, 2000. Revision accepted November 17, 2000. Reprint requests: Emel Ceylan, Hacettepe University Medical School, Department of Nuclear Medicine, 06100 Sihhiye, Ankara, Turkey. E-mail: [email protected]
Missed diagnosis of influenza B virus due to nucleoprotein sequence mutations, Singapore, April 2011
Authors: H K Lee, C K Lee, T P Loh, D Chiang, E S Koay, J W Tang
Journal: Eurosurveillance (2011)

A new influenza B variant was discovered in Singapore in April 2011 during diagnostic testing of a 3-year-old boy with respiratory symptoms. Influenza B virus was isolated from culture and confirmed by standard immunofluorescence testing, but was not detected by the routine, in-house influenza screening reverse-transcription polymerase chain reaction assay that targets the nucleoprotein (NP) gene. Subsequent sequencing investigations demonstrated that several other published assays targeting NP could also fail to detect this novel variant.
Abstract 1442: Understanding the role of autophagy during cancer metastasis
Authors: Maegan M. Lim, Ziqiang Teo, Chee Chong Choo, Pengcheng Zhu, Nguan Soon Tan
Journal: Cancer Research (2015)

Abstract Introduction: Autophagy is a catabolic process that involves the lysosomal degradation and recycling of cellular components. It acts as a cell protective mechanism to promote cellular homeostasis or survival during nutrient deprivation. Studies in the past decade have shown the involvement of autophagy during tumorigenesis, but much are left to be debated on its controversial role as a tumour suppressor or a potential protective role in promoting cancer cell survival. Knockout of autophagic core machinery proteins in mice models showed increase potential of tumorigenic development. Recent findings also suggested that autophagy plays a part during cancer cell metastasis, but till date, there is no significant evidence to clearly define the involvement of autophagy and the mechanistic behind it. Our study involves defining the role of autophagy during metastasis and the molecular drivers behind the process. Material &amp; Methods: Using human squamous cell carcinoma cell lines, we induce epithelial-mesenchymal transition (EMT) with three different methods to study the change in the autophagy level during the process. Results: Our unpublished data have demonstrated a higher autophagy level during our three models of EMT induction. Guided by the microarray data, we investigated the molecular drivers behind the change in autophagy levels and showed evidence that knocking down of certain molecular drivers reverses the effect and delay EMT. Citation Format: Maegan M. Lim, Ziqiang Teo, Chee Chong Choo, Pengcheng Zhu, Nguan Soon Tan. Understanding the role of autophagy during cancer metastasis. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1442. doi:10.1158/1538-7445.AM2015-1442
Abstract IA21: Mutant p53 activities in tumor development.
Authors: Guillermina Lozano
Journal: Clinical Cancer Research (2016)

Abstract Alterations in the p53 tumor suppressor gene stand out as the most common alteration in many cancers including 96% of ovarian serous carcinoma. The fact that most p53 alterations in tumors are missense mutations suggests that cells expressing mutant p53 have an inherent biologic advantage (often termed gain of function (GOF)) over tumors lacking p53. Mouse models directly examined the role of p53 mutants in tumorigenesis and show an increased invasiveness and aggressive nature of mutant p53 tumors as opposed to those lacking p53. An additional prerequisite for GOF is the stabilization of mutant p53 proteins by various signaling pathways. The emerging themes by which mutant p53 exhibits its gain of function are 1) through formation of mutant p53 complexes with other proteins that modify their activities (p63 and p73, for example), and 2) by interaction of mutant p53 with other transcription factors (SREBP and Ets2, for example) that bring a potent transcriptional activation domain to promoters not normally regulated by wild type p53. An understanding of the mechanisms that drive mutant p53 activities in ovarian serous carcinoma is needed. Citation Format: Guillermina Lozano. Mutant p53 activities in tumor development. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr IA21.
IgG4-Related Kidney Disease in a Patient With History of Breast Cancer
Authors: Simone Krebs, Serena Monti, Surya Seshan, Josef Fox, Lorenzo Mannelli
Journal: Clinical Nuclear Medicine (2016)

A 64-year-old African American woman with history of stage III breast carcinoma, 3 years after complete response to therapy, presents with progressive fatigue, increasing arthralgia, and unintentional weight loss of 15 lb in 3 months. An 18F-FDG PET demonstrated new diffuse FDG avidity of the renal parenchyma, new FDG-avid foci in pancreas and lungs, and new FDG-avid lymph nodes above and below the diaphragm. While a retroperitoneal lymph node biopsy was inconclusive, a kidney biopsy resulted in diagnosis of diffuse, severe, IgG4-related tubulointerstitial nephritis. Treatment with corticosteroid led to complete resolution of the symptoms and PET findings.
Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease
Authors: Deepak Kumar Vijaya Kumar, Se Hoon Choi, Kevin J. Washicosky, William A. Eimer, Stephanie Tucker, Jessica Ghofrani, Aaron Lefkowitz, Gawain McColl, Lee E. Goldstein, Rudolph E. Tanzi, Robert D. Moir
Journal: Science Translational Medicine (2016)

β-Amyloid protein oligomerization and fibrillization, known to be pathogenic in Alzheimer’s disease, may play a physiological role in microbial entrapment and innate immunity.
The Histopathology of the Macroglobulinemia of Waldenström
Authors: Thomas F. Dutcher, John L. Fahey
Journal: JNCI Journal of the National Cancer Institute (1959)

Journal Article The Histopathology of the Macroglobulinemia of Waldenström Get access Thomas F. Dutcher, Thomas F. Dutcher Search for other works by this author on: Oxford Academic PubMed Google Scholar John L. Fahey John L. Fahey Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 22, Issue 5, May 1959, Pages 887–916, https://doi.org/10.1093/jnci/22.5.887 Published: 01 May 1959 Article history Received: 13 January 1959 Published: 01 May 1959
Neuropsychiatric manifestations of altered thyroid state
Authors: K D Denicoff, R T Joffe, M C Lakshmanan, J Robbins, D R Rubinow
Journal: American Journal of Psychiatry (1990)

The authors assessed the mood and cognitive effects of sequential T4, T3, and withdrawal of thyroid hormone replacement on 25 patients who had had thyroidectomies for thyroid cancer. The patients experienced increased sadness and anxiety when they were without medication, but not significant difference in mood was noted between T4 and T3. The patients who experienced increased affective symptoms when not taking medication were more likely to have histories of affective illness or mood lability.
Abstract MS2-2: Genomics to personalize therapy of metastatic breast cancers
Authors: F André
Journal: Cancer Research (2016)

Abstract Genomic studies have shown that breast cancer includes large number of rare genomic segments. This led to the development of precision medicine where sequencing could be used to identify drivers in individuals, that would be treated accordingly. 10 to 20 molecular alterations are being investigated in the context of biomarker-driven therapeutic trials. This includes PIK3CA, AKT1, ERBB2, PTEN, BRCA1/2, ESR1 mutations, FGFR1, CCND1 amplifications, AR expression. Beyond the question of clinical utility of detecting these variants, there are several challenges that precision medicine is facing in breast cancer. The first challenge will be to better define which genomic alterations are drivers in individuals and how to target them. The recent failures of prospective trials testing precision medicine (SAFIR01, SHIVA) highlights the need to better understand what defines a targetable alteration. These trials also pointed out the need to target the molecular alterations, rather than the pathway. Also, it's important to better understand the role that alterations on multiple drivers could play on resistance. As illustration, several reports suggest that PIK3CA mutations could be associated to a lower sensitivity to dual Her2 inhibition in neoadjuvant setting. The second challenge will be to generate genomic tests that predict the sensitivity of therapies that target pathways, like mTOR or CDK4 inhibitors. To this regards, gene expression looks particularly attractive since it allows quantifying pathway activation. The third challenge will be to predict earlier the resistance to targeted therapies. The development of circulating DNA as a diagnostic tool could be useful for early diagnosis of resistance. Clinical trials testing this technology are currently starting. Finally, one of the major challenge will be to integrate immunotherapeutics in the application field of precision medicine. High mutational loads and neoantigen expression could predict efficacy of immunotherapeutics. Further combination with targeted therapies should be rationalized based on genomics. Overall, while candidate biomarkers exist and technologies are available, precision medicine failed to deliver until now for patients with metastatic breast cancer. Nevertheless, ongoing randomized trials testing drugs according to genomic alterations should open the door of treatment decisions based on genomics for breast cancer patients. Citation Format: André F. Genomics to personalize therapy of metastatic breast cancers. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr MS2-2.
HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes
Authors: Shahnam Sharif, Yolanda van der Graaf, Hendrik M. Nathoe, Harold W. de Valk, Frank L.J. Visseren, Jan Westerink
Journal: Diabetes Care (2016)

OBJECTIVE To evaluate whether low HDL cholesterol (HDL-c) levels are a risk factor for cardiovascular disease and mortality in patients with type 2 diabetes and whether it remains a residual risk factor when attaining low LDL cholesterol (LDL-c) treatment goals or when LDL-c is treated with intensive lipid-lowering therapy. RESEARCH DESIGN AND METHODS We performed a prospective cohort study of 1,829 patients with type 2 diabetes included in the Second Manifestations of ARTerial disease (SMART) cohort. Cox proportional hazard models were used to evaluate the risk of HDL-c on cardiovascular events and all-cause mortality. Analyses were performed in strata of LDL-c levels (&amp;lt;2.0, 2.0–2.5, and &amp;gt;2.5 mmol/L) and lipid-lowering therapy intensity and were adjusted for age, sex, BMI, smoking, alcohol, LDL-c, triglycerides, systolic blood pressure, estimated glomerular filtration rate, glucose, and HbA1c. RESULTS A total of 335 new cardiovascular events and 385 deaths occurred during a median follow-up of 7.0 years (interquartile range 3.9–10.4). No relation was found between plasma HDL-c and cardiovascular events (hazard ratio [HR] 0.97, 95% CI 0.93–1.01) or all-cause mortality (HR 0.99, 95% CI 0.96–1.03). Subgroup analysis supported effect modification by plasma LDL-c levels. In patients with LDL-c levels &amp;lt;2.0 mmol/L, higher HDL-c was related to higher risk for all-cause mortality (HR 1.14, 95% CI 1.07–1.21). Higher HDL-c was also related to higher risk for cardiovascular events in patients with LDL-c levels &amp;lt;2.0 mmol/L (HR 1.10, 95% CI 1.07–1.21) in contrast to patients with LDL-c levels between 2.0 and 2.5 mmol/L (HR 0.85, 95% CI 0.75–0.95) and &amp;gt;2.5 mmol/L (HR 0.96, 95% CI 0.91–1.00). CONCLUSIONS In high-risk patients with type 2 diabetes with LDL-c levels &amp;lt;2.0 mmol/L, higher HDL-c at baseline is unexpectedly related to a higher risk for cardiovascular events and all-cause mortality in contrast to high-risk patients with type 2 diabetes with LDL-c levels between 2.0 and 2.5 mmol/L.
Recruiting individuals into the HTLV cohort study in the United Kingdom: clinical findings and challenges in the first six years, 2003 to 2009
Authors: L J Brant, C Cawley, K L Davison, G  P Taylor, collective the HTLV National Register Steering Group
Journal: Eurosurveillance (2011)

Human T-lymphotropic virus (HTLV) infection is rare in the United Kingdom (UK) and few studies are available worldwide. Following introduction of blood donation testing in 2002, a cohort of individuals could be identified and prospectively recruited to describe progression and onset of disease. Here we describe baseline characteristics of participants, and evaluate recruitment into the UK HTLV National Register over the first six years, from July 2003 to June 2009. A multicentre cohort study recruited participants from the UK blood services (recipients and donors) and specialist HTLV clinics. Almost half of the 148 participants recruited were blood donors, nine were blood transfusion recipients, 40 contacts and 29 clinic attendees (nine asymptomatic and 20 symptomatic). Most participants were HTLV-1 positive (n=115); 11 had HTLV-2 and 22 were HTLV-negative. Baseline self-completion questionnaires were received for 83%. The most commonly reported condition was a past operation/serious illness (69%). Twenty-six participants reported four or more possible signs/symptoms of HTLV-1-associated myelopathy/tropical spastic paraparesis. Recruitment into a study of a rare, long-term infection is challenging. This cohort will enable descriptions of HTLV-associated disease progression amongst people recruited from varying sources; it is the first prospective study of its kind in Europe.
Erratum: Corrigendum: Laterodorsal tegmentum interneuron subtypes oppositely regulate olfactory cue-induced innate fear
Authors: Hongbin Yang, Junhua Yang, Wang Xi, Sijia Hao, Benyan Luo, Xiaobin He, Liya Zhu, Huifang Lou, Yan-qin Yu, Fuqiang Xu, Shumin Duan, Hao Wang
Journal: Nature Neuroscience (2016)
Inhibitory Effect of Some Aminoazo Dyes and Other Carcinogens on Glutamate Oxidation in Mitochondria of Riboflavine-Deficient Rat Liver
Authors: Ruth K. Kielley
Journal: JNCI Journal of the National Cancer Institute (1957)

Inhibitory Effect of Some Aminoazo Dyes and Other Carcinogens on Glutamate Oxidation in Mitochondria of Riboflavine-Deficient Rat Liver Get access Ruth K. Kielley Ruth K. Kielley Laboratory of Biology, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 19, Issue 6, December 1957, Pages 1077–1085, https://doi.org/10.1093/jnci/19.6.1077 Published: 01 December 1957 Article history Received: 18 June 1957 Published: 01 December 1957
Responses of Seven Inbred Strains of Mice to Percutaneous Applications of 3-Methylcholanthrene
Authors: Howard B. Andervont, John H. Edgcomb
Journal: JNCI Journal of the National Cancer Institute (1956)

Responses of Seven Inbred Strains of Mice to Percutaneous Applications of 3-Methylcholanthrene Get access Howard B. Andervont, Howard B. Andervont Laboratory of Biology and Laboratory of Pathology, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar John H. Edgcomb John H. Edgcomb Laboratory of Biology and Laboratory of Pathology, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 17, Issue 4, October 1956, Pages 481–495, https://doi.org/10.1093/jnci/17.4.481 Published: 01 October 1956 Article history Received: 05 June 1956 Published: 01 October 1956
Serotoninergic agents in the treatment of isolated sleep paralysis
Authors: S Snyder, G Hams
Journal: American Journal of Psychiatry (1982)

The authors report three cases of isolated sleep paralysis controlled by L-tryptophan with or without amitriptyline. Both agents increase CNS 5-hydroxytryptamine availability, whereas imipramine, which was ineffective in the one case in which it was tried, affects predominantly norepinephrine reuptake.
Collection, Tumor Contamination, and Engraftment Kinetics of Highly Purified Hematopoietic Progenitor Cells to Support High Dose Therapy in Multiple Myeloma
Authors: G. Tricot, Y. Gazitt, T. Leemhuis, S. Jagannath, K.R. Desikan, D. Siegel, A. Fassas, S. Tindle, J. Nelson, C. Juttner, A. Tsukamoto, J. Hallagan, K. Atkinson, C. Reading, R. Hoffman, B. Barlogie
Journal: Blood (1998)
Managing the Risks of Concurrent Surgeries
Authors: Michelle M. Mello, Edward H. Livingston
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal